Add BrightSurf on Google Email

Chinese Medical Journal Review highlights stable CircRNAs as non‑invasive biomarkers for cancer detection and therapy

Circulating circRNAs show high cell-type and tissue specificity, making them ideal for non-invasive cancer management. They can be detected in multiple body fluids and reflect treatment response, positioning them as functional drivers of therapy resistance.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateJul 28, 2026

Immune cells use previously unknown pathway to eliminate AML

Scientists at MD Anderson Cancer Center have identified a previously unknown mechanism by which T cells attack and eliminate acute myeloid leukemia (AML) cells. The discovery reveals that AML cells use a CD64-dependent pathway to evade traditional MHC recognition, potentially explaining why AML is sensitive to immune-based treatments.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalProceedings of the National Academy of Sciences·DateJul 15, 2026

Scientists develop new, improved method to find and isolate the strongest cancer-fighting immune cells

A new method called ATTACH identifies strong interactions between T cells and cancer-specific proteins to isolate effective tumor-reactive T cells. This approach overcomes key challenges in immunotherapy development, offering a rapid and accessible way for isolating rare immune cells.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalJournal for ImmunoTherapy of Cancer·DateJul 8, 2026

Intravesical CAR T therapy opens door to bladder-sparing cancer treatment

Researchers developed genetically engineered CAR T cells specifically targeting bladder cancer cells and delivered them directly to the bladder via a catheter. This approach shows promise in controlling bladder tumors in mice and may be effective in humans, offering an alternative to life-altering procedures like bladder removal.

SourceRockefeller University Press·JournalJournal of Experimental Medicine·TypeExperimental study·DateJun 26, 2026

UCLA researchers awarded $1.7 million Department of Defense grant to advance next-generation CAR T-cell therapies for prostate cancer

Researchers at UCLA Health Jonsson Comprehensive Cancer Center receive $1.7M grant to advance CAR T-cell therapies for metastatic castration-resistant prostate cancer. They will investigate a new approach combining engineered nanovial technology with single-cell analysis to rapidly evaluate and optimize dual-targeted CAR T-cell therapies.

Spatial map of bladder cancer reveals hidden tumor environments and new paths toward precision therapy

A spatial map of muscle-invasive bladder cancer reveals organized tumor cell states, immune environments, and therapeutic vulnerabilities. Luminal-like cells are found in tumor cores with relevant therapeutic markers, while basal-like cells near margins show signs of aggressiveness. This study guides treatment strategies by accounting ...

Researchers identify target with potential to improve CAR T-cell therapy response in patients with blood cancers

Researchers have identified a protein called cathepsin B that can prevent CAR T-cells from tearing off fragments from cancer cells, allowing them to stay active longer and fight cancer more effectively. This breakthrough could lead to improved durability and outcomes for patients with recurrent or difficult-to-treat blood cancers.

SourceUniversity of Maryland School of Medicine·JournalSignal Transduction·DateJun 15, 2026

UMass Amherst researchers combine bacteria and viruses to demonstrate a new way to fight cancer

Researchers at UMass Amherst have designed a new therapy that combines engineered Salmonella bacteria with oncolytic viruses to target liver and pancreatic cancer. The treatment showed promising results in animal models, leading to significant tumor reduction and improved survival rates.

SourceUniversity of Massachusetts Amherst·JournalCell Reports Medicine·TypeRandomized controlled/clinical trial·DateJun 3, 2026

Research alert: UC San Diego study uncovers molecular “shield” behind cancer immunotherapy resistance

Researchers identified microRNA-25 as a key player in creating an immune-suppressive tumor environment that resists cancer immunotherapy. Removing miR-25 reshaped the environment and activated anti-tumor immune responses, suggesting a potential target for converting 'cold' tumors into responsive 'hot' tumors.

SourceUniversity of California - San Diego·JournalNature Communications·DateJun 1, 2026

NEJM/ASCO: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma in landmark international trial

In a landmark international trial, teclistamab outperformed standard treatments in extending survival and remission for patients with relapsed multiple myeloma. Nearly 70% of patients remained disease-free after 18 months, and nearly two-thirds achieved complete remission.

SourceUniversity of Miami Miller School of Medicine·JournalNew England Journal of Medicine·DateMay 29, 2026

Study identifies new marker to find patients with advanced prostate cancer more likely to benefit from combination immunotherapy

Researchers discovered a new gene expression signature linked to prolonged overall survival in patients with metastatic castration-resistant prostate cancer who responded to combined immune checkpoint inhibitors. The biomarker has the potential to help identify patients most likely to benefit from this treatment combination.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalNature Communications·DateMay 20, 2026

Overcoming a blind spot in cancer immunotherapy

Researchers at the Francis Crick Institute have developed a new method to enhance anti-cancer immunity by redirecting non-specialized immune cells to present a broader range of tumor antigens. This approach, leveraging understanding of dendritic cell biology, has shown promise in reducing tumour growth and amplifying responses in mice.

SourceThe Francis Crick Institute·JournalNature Cancer·DateMay 20, 2026

Tiny materials, stronger antitumor immunity

Researchers review how engineered nanomaterials can be used to deliver antigens, improve antigen presentation, support T cell priming and infiltration, and reshape tumor niches. The materials are designed to intervene across the cancer-immunity cycle, improving immune activation while reducing off-target effects.

SourceChina Anti-Cancer Association·JournalCancer Biology & Medicine·DateMay 17, 2026

Combination therapy with stem cell-derived immune cells boost anti-cancer response

A recent study reveals that combining iNKT cell therapy with antigen-presenting cells activated by a lipid compound triggers effective antitumor immunity. The therapy generates memory-phenotype T cells that can recognize and respond to specific threats, offering a promising personalized approach to cancer treatment.

SourceChiba University·JournalStem Cell Research & Therapy·TypeExperimental study·DateMay 7, 2026